Ivacaftor withdrawal syndrome: A potentially life-threatening consequence from a life-saving medication

J Cyst Fibros. 2022 May;21(3):549-550. doi: 10.1016/j.jcf.2021.07.021. Epub 2021 Aug 11.

Authors

James M Clegg¹, Kelsey W Malloy², Rebekah F Brown², Alison G Grisso², Andrew G Sokolow²

Affiliations

¹ Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, 2200 Children's Way, Nashville, TN 37232, USA. Electronic address: [email protected].
² Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, 2200 Children's Way, Nashville, TN 37232, USA.

PMID: 34391678
DOI: 10.1016/j.jcf.2021.07.021

No abstract available

Keywords: Cystic fibrosis; Highly effective modulator therapy; Ivacaftor withdrawal syndrome.

Publication types

Letter

MeSH terms

Aminophenols / therapeutic use
Benzodioxoles / therapeutic use
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / complications
Cystic Fibrosis* / drug therapy
Humans
Mutation
Quinolones* / adverse effects

Substances

Aminophenols
Benzodioxoles
Quinolones
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor